IL151243A0 - Use of a compound which is an activator or ligand of a peroxisome proliferator-activated receptor for manufacture of a medicament - Google Patents

Use of a compound which is an activator or ligand of a peroxisome proliferator-activated receptor for manufacture of a medicament

Info

Publication number
IL151243A0
IL151243A0 IL15124301A IL15124301A IL151243A0 IL 151243 A0 IL151243 A0 IL 151243A0 IL 15124301 A IL15124301 A IL 15124301A IL 15124301 A IL15124301 A IL 15124301A IL 151243 A0 IL151243 A0 IL 151243A0
Authority
IL
Israel
Prior art keywords
activator
ligand
medicament
manufacture
compound
Prior art date
Application number
IL15124301A
Other languages
English (en)
Original Assignee
Univ Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield filed Critical Univ Sheffield
Publication of IL151243A0 publication Critical patent/IL151243A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15124301A 2000-02-15 2001-02-15 Use of a compound which is an activator or ligand of a peroxisome proliferator-activated receptor for manufacture of a medicament IL151243A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003310.0A GB0003310D0 (en) 2000-02-15 2000-02-15 Bone formation
PCT/GB2001/000626 WO2001060355A1 (en) 2000-02-15 2001-02-15 Modulation of bone formation

Publications (1)

Publication Number Publication Date
IL151243A0 true IL151243A0 (en) 2003-04-10

Family

ID=9885521

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15124301A IL151243A0 (en) 2000-02-15 2001-02-15 Use of a compound which is an activator or ligand of a peroxisome proliferator-activated receptor for manufacture of a medicament

Country Status (18)

Country Link
US (1) US20030139372A1 (pt)
EP (1) EP1259233A1 (pt)
JP (1) JP2003522787A (pt)
KR (1) KR20020093808A (pt)
CN (1) CN1430512A (pt)
AU (1) AU3212101A (pt)
BR (1) BR0108344A (pt)
CA (1) CA2399810A1 (pt)
CZ (1) CZ20022741A3 (pt)
GB (1) GB0003310D0 (pt)
HK (1) HK1049618A1 (pt)
HU (1) HUP0204511A3 (pt)
IL (1) IL151243A0 (pt)
MX (1) MXPA02007901A (pt)
NO (1) NO20023837L (pt)
NZ (1) NZ520764A (pt)
WO (1) WO2001060355A1 (pt)
ZA (1) ZA200206318B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
CA2525695A1 (en) * 2003-05-28 2004-12-09 Isao Chinen Compositions and foods and drinks containing higher fatty acid derivative
US20050054663A1 (en) * 2003-08-13 2005-03-10 Bennett Christina N. GSK-3 inhibitors
EP2100877B1 (en) * 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP2243766B1 (en) * 2003-09-19 2015-09-02 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids for use in treating PPAR-delta mediated conditions
JPWO2006126541A1 (ja) * 2005-05-27 2008-12-25 塩野義製薬株式会社 ビタミンｋ類含有医薬組成物
NO20053517L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av lipidsenkende midler
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
CN101945653B (zh) * 2008-01-02 2013-01-16 海洋生物有限公司 用于治疗神经变性疾病的组合物和方法
WO2010137944A1 (en) 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia
EP2815241A2 (en) * 2012-02-15 2014-12-24 Basf Se Means and methods for assessing bone disorders
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
CN105327333B (zh) * 2015-10-30 2018-09-07 大连大学 可促进牙种植体周围成骨的口腔施用组合物及其制剂
CN110433156A (zh) * 2019-08-27 2019-11-12 成都元素平衡生物科技有限公司 芝麻素在成骨分化中的新应用
US20220331267A1 (en) * 2019-09-05 2022-10-20 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
CN111789833A (zh) * 2020-08-31 2020-10-20 苏州大学 2-溴棕榈酸在制备防治骨丢失相关疾病的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
JPH09295936A (ja) * 1996-04-30 1997-11-18 Kowa Techno Saac:Kk 人工透析患者の骨疾患治療用外用剤
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
WO1999024032A1 (en) * 1997-11-10 1999-05-20 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
GB9824614D0 (en) * 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US20030139372A1 (en) 2003-07-24
CN1430512A (zh) 2003-07-16
HK1049618A1 (zh) 2003-05-23
CZ20022741A3 (cs) 2003-03-12
AU3212101A (en) 2001-08-27
HUP0204511A2 (en) 2003-05-28
NO20023837L (no) 2002-10-14
KR20020093808A (ko) 2002-12-16
NZ520764A (en) 2004-05-28
JP2003522787A (ja) 2003-07-29
HUP0204511A3 (en) 2004-11-29
CA2399810A1 (en) 2001-08-23
WO2001060355A1 (en) 2001-08-23
NO20023837D0 (no) 2002-08-14
GB0003310D0 (en) 2000-04-05
ZA200206318B (en) 2003-11-07
EP1259233A1 (en) 2002-11-27
BR0108344A (pt) 2003-03-11
MXPA02007901A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
IL151243A0 (en) Use of a compound which is an activator or ligand of a peroxisome proliferator-activated receptor for manufacture of a medicament
IL158873A0 (en) Modulators of peroxisome proliferator activated receptors
IL158332A0 (en) Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
TW200716572A (en) Peroxisome proliferator activated receptor alpha agonists
IL213806A0 (en) Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions
AU2003287965A8 (en) Modulation of peroxisome proliferator activated receptors activity
HK1064035A1 (en) Pharmaceutical salts of 1-phenyl-3-dimethylamino-propane compounds
PL350312A1 (en) Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB2387333B (en) Outer needle device of a catheter
HK1087337A1 (en) Use of a hif-alpha stabilizing agent for the preparation of medicament for treatment of diabetes
HK1049954B (zh) 複合的衛生巾
GB0207460D0 (en) A device for the picture-proving diagnosis of tissue
AU2002224138A1 (en) Peroxisome proliferator activated receptor d activators
IL161578A0 (en) Peroxisome proliferator activated receptor agonists
AU2002330544A1 (en) Use of an oil of the gourd family for inhibiting 5$g(a)-reductase activity
JO2409B1 (en) Second-phenyl carboxy amides are useful as lipid-lowering agents
AU2001229378A1 (en) Antisense modulation of peroxisome proliferator-activated receptor gamma expression
WO2003022844A3 (en) Synthesis of epothilones intermediates thereto and analogues thereof
DE60142038D1 (de) Aktivatoren des peroxisome proliferator-activated rezeptors
WO2004032967A8 (fr) Association entre un ligand des ppar et un agent antioxydant et utilisation dans le traitement de l'obesite
AU2001254712A1 (en) Use of organophosphorous compounds for producing a medicament for treating infections
HUP0203900A3 (en) Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments
AU2002307327A1 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
HUP0102191A3 (en) Use of oxazolidinones for the preparation of a medicament for transdermal delivery
AU2001236266A1 (en) Use of a compound for preparing a drug